Proteome Sciences PLC Option Awards (4288B)

TIDMPRM

RNS Number : 4288B

Proteome Sciences PLC

04 April 2017

Proteome Sciences plc

(the "Company" or the "Group")

Option Awards

Proteome Sciences plc (AIM:PRM) announces the award of 18,160,000 nominal cost options ("Options") over ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") to certain executive directors on 3 April 2017 (the "Award") as detailed below. The Options represent 6.17% of the current issued share capital of the Company and lapse on 3 April 2027 ("Lapse Date").

 
   Director      Current           New          New        Total   Percentage    Vesting 
                 options    Unapproved          EMI      Options    of Issued       Date 
                    Held       Options      Options         Held        Share 
                                                                      Capital 
 Jeremy                                                                          01 June 
  Haigh              Nil     4,000,000    5,000,000    9,000,000         3.1%       2019 
                                                                                03 April 
 Ian Pike        165,583           Nil    3,750,000    3,915,583         1.3%       2020 
 Richard                                                                        03 April 
  Dennis             Nil           Nil    3,250,000    3,250,000         1.1%       2020 
                                                                                03 April 
 Geoff Ellis     300,000     2,160,000          Nil    2,460,000         0.8%       2020 
               ---------  ------------  -----------  ----------- 
 TOTAL           465,583     6,160,000   12,000,000   18,625,583 
 

The Options will vest subject to the holders remaining employed until the vesting date and the satisfaction of the following performance requirements ("Performance Criteria") relating to the growth in the Company's share price, as quoted on the London Stock Exchange:

i. One third of the total Options awarded will vest if the Company's closing share price over a 5-day period attains 7p at any time after the Vesting Date but before the Lapse Date (the "Exercise Period");

ii. A further one third of the total Options awarded will vest if the Company's closing share price over a 5-day period attains 9p at any time during the Exercise Period; and

iii. The final one third of the total Options awarded will vest if the Company's closing share price over a 5-day period attains 11p at any time during the Exercise Period.

Once the Options have vested in accordance with the Performance Criteria, participants can exercise their Options at any time during the period commencing from the Vesting Date and ending on the Lapse Date.

Following the Award, the Company now has 19,526,548 options over Ordinary Shares outstanding representing 6.63% of the current issued share capital of the Company.

 
 For further information: 
 
   Proteome Sciences plc                   Tel: [phone] 
   Dr Jeremy Haigh, Chief Executive        865065 
   Officer 
   Dr Ian Pike, Chief Scientific 
   Officer 
   Geoff Ellis, Finance Director 
 
   finnCap Limited (Nominated              Tel: +44 (0) 207 
   Adviser/Broker)                         220 0500 
   Geoff Nash/James Thompson 
   Tony Quirke (Broking) 
 
   IFC Advisory (Financial PR              Tel: +44 (0) 203 
   and IR)                                 053 8761 
   Tim Metcalfe/Graham Herring/Miles 
   Nolan 
 
 

Notes for editors:

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant(R) , TMTcalibrator(TM) ) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services(TM) division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014.

 
1.  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name                                                         Jeremy Haigh 
2.  Reason for the Notification 
a)  Position/status                                              Chief Executive Officer 
b)  Initial notification/Amendment                               Initial notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                                         Proteome Sciences plc 
b)  LEI                                                          n/a 
4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
     each type of transaction; (iii) each date; and (iv) each place where transactions have been 
     conducted 
a)  Description of the Financial instrument, type of instrument  Options over Ordinary Shares of 1p each 
    Identification code                                          GB0003104196 
b)  Nature of the transaction                                    Award of options 
c)  Price(s) and volume(s)                                       4,000,000 Unapproved Options 
                                                                  5,000,000 EMI Options 
d)  Aggregated information: 
     - Aggregated volume                                           9,000,000 Options over Ordinary Shares of 1p each 
     - Price 
e)  Date of the transaction                                      3 April 2017 
f)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON) 
 
 
1.  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name                                                         Ian Pike 
2.  Reason for the Notification 
a)  Position/status                                              Chief Scientific Officer 
b)  Initial notification/Amendment                               Initial notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                                         Proteome Sciences plc 
b)  LEI                                                          n/a 
4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
     each type of transaction; (iii) each date; and (iv) each place where transactions have been 
     conducted 
a)  Description of the Financial instrument, type of instrument  Options over Ordinary Shares of 1p each 
    Identification code                                          GB0003104196 
b)  Nature of the transaction                                    Award of Options 
c)  Price(s) and volume(s)                                       3,750,000 EMI Options 
d)  Aggregated information: 
     -- Aggregated volume                                          3,750,000 Options over Ordinary Shares of 1p each 
     -- Price 
e)  Date of the transaction                                      3 April 2017 
f)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON) 
 
 
1.  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name                                                         Richard Dennis 
2.  Reason for the Notification 
a)  Position/status                                              Chief Commercial Officer 
b)  Initial notification/Amendment                               Initial notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                                         Proteome Sciences plc 
b)  LEI                                                          n/a 
4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
     each type of transaction; (iii) each date; and (iv) each place where transactions have been 
     conducted 
a)  Description of the Financial instrument, type of instrument  Options over Ordinary Shares of 1p each 
    Identification code                                          GB0003104196 
b)  Nature of the transaction                                    Award of Options 
c)  Price(s) and volume(s)                                       3,250,000 EMI Options 
d)  Aggregated information: 
     -- Aggregated volume                                          3,250,000 Options over Ordinary Shares of 1p each 
     -- Price 
e)  Date of the transaction                                      3 April 2017 
f)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON) 
 
 
1.  Details of the person discharging managerial responsibilities / person closely associated 
a)  Name                                                         Geoff Ellis 
2.  Reason for the Notification 
a)  Position/status                                              Finance Director 
b)  Initial notification/Amendment                               Initial notification 
3.  Details of the issuer, emission allowance market participant, auction platform, auctioneer 
     or auction monitor 
a)  Name                                                         Proteome Sciences plc 
b)  LEI                                                          n/a 
4.  Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
     each type of transaction; (iii) each date; and (iv) each place where transactions have been 
     conducted 

a)  Description of the Financial instrument, type of instrument  Ordinary Shares of 1p each 
    Identification code                                          GB0003104196 
b)  Nature of the transaction                                    Award of Options 
c)  Price(s) and volume(s)                                       2,160,000 Unapproved Options 
d)  Aggregated information: 
     -- Aggregated volume                                          2,160,000 Options over Ordinary Shares of 1p each 
     -- Price 
e)  Date of the transaction                                      3 April 2017 
f)  Place of the transaction                                     London Stock Exchange, AIM Market (XLON) 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHIJMATMBBMBRR

(END) Dow Jones Newswires

April 04, 2017 02:01 ET (06:01 GMT)